BEVERLY, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an instrument for automated multiplex PCR testing for veterinary diagnostics, today announced it has finalized the design of the MiQLab™ Pneumonia Panel for companion animals and completed initial multiplex testing.
LexaGene Finalizes Design of Pneumonia Panel
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
